Navigation Links
Neurocrine Biosciences Presents Elagolix Data
Date:6/16/2009

SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that data from Phase I and Phase II elagolix trials and preclinical work was presented at the 91st Annual Meeting of the Endocrine Society (ENDO 09) in Washington DC, June 10-13, 2009.

The first clinical abstract presentation at ENDO 09 reviews the results of a Phase I study in which elagolix was evaluated over six weeks (42 days) in 60 healthy premenopausal women. The study was a double-blind, placebo-controlled study in parallel groups in which 88% of the participants completed the treatment period. The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and endocrine effects of elagolix. The results of this study showed that daily administration of elagolix induced partial suppression of gonadotropins for 12-18 hours per day with a return to baseline each morning for 42 days. The effect on gonadotropins translated in a dose related fashion to maintenance of low estradiol levels over the six week period without inducing severe hot flashes or excessive bone resorption as determined by n-telopeptide. Consistent pharmacokinetic profiles were maintained throughout the 42 days of treatment, and adverse events were comparable among the placebo and elagolix groups.

The second clinical abstract at ENDO 09 reports results from a Phase II study where the safety of elagolix was evaluated in 252 women with a confirmed diagnosis of endometriosis. The study was a randomized, double-blind study of elagolix and depo-subQ provera 104 (used as an active control) administered over six months followed by six months of additional assessments. The primary endpoint of the study was to assess the impact of elagolix on bone mineral density using dual energy x-ray absorptiometry (DXA) scanning at months six and twelve. The
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
2. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Reports First Quarter 2008 Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
7. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
9. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
10. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... 24, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the first fiscal ... overview: , Revenues of $47.5 million, up 10% ... of $0.21, up 50% over last year,s comparable quarter. ... of $7.2 million, up 20% over last year,s comparable ...
(Date:7/24/2014)... -- Amgen (NASDAQ: AMGN ) today announced that ... July 29, 2014, after the close of the U.S. financial ... with the investment community at 2 p.m. PT. Participating in ... , chairman and chief executive officer, and other members of ... conference call will be simultaneously broadcast over the Internet and ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 Drexel University ... D. Weber, MD, MS, FACP, has been appointed vice dean ... will join Drexel from The Commonwealth Medical College, where she ... dean for clinical affairs, and professor of medicine. , ... Commonwealth Medical College, Weber had a major role in many ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... sent patients to designated cardiac receiving centers dramatically increased ... in Arizona, according to a study published online yesterday ... , "We knew lives would be saved if the ... arrest care and we were able to get cardiac ... done for Level 1 trauma patients," said lead study ...
(Date:7/25/2014)... Parkulture is proud to ... parkour instructor, Jared “JJ” Woods, will be competing on ... Ninja Warrior. The show will premiere on local affiliates ... rerun on the new Esquire Network on Tuesday, July ... has been balancing careers as a professional stuntman for ...
(Date:7/25/2014)... 2014 In today’s technological era, every ... supporting devices. This benefits the organization in various ways. ... attacks which can destroy the confidential information and processes ... and Compliance (EGRC) manage and protect the enterprise from ... cause loss in dollars to the comp may. The ...
Breaking Medicine News(10 mins):Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6
... may be the way to make a living, but it ... new study from the Universit de Montral, office-workers have become ... activity may partly explain the rise in obesity. Their findings, ... , may have health implications for the millions of people ...
... , MONDAY, Oct. 4 (HealthDay News) -- Children whose ... brain chemical serotonin because of gene mutations may be ... later in life, Norwegian researchers report. Serotonin ... important role during development, especially in the development of ...
... of chronic diseases to the top of the EU ... Kidney Health , the EU Diabetes Working Group and ... the European Parliament, together with representatives of health professionals and ... these chronic diseases urgently, they threaten the "Europe 2020 strategy", ...
... CHANGES , The use of a nasal continuous positive ... may cause craniofacial changes in adults with obstructive sleep ... Vancouver, BC, Canada, analyzed baseline and follow-up radiographs from ... for a minimum of 2 years. Changes in craniofacial ...
... SAN FRANCISCO Implementing a Medical Home practice model ... provide comprehensive care to more patients, and to offer ... with their doctors, recommendations and reduce emergency room visits ... 4, 2010, at the American Academy of Pediatrics (AAP) ...
... -- A new vaccine added to standard therapy appears to ... the most deadly form of brain cancer, according to a ... University of Texas MD Anderson Cancer Center. The vaccine ... most aggressive form of the disease. "About a third ...
Cached Medicine News:Health News:Is your job making you fat? 2Health News:New Clues to Possible Genetic Basis for ADHD 2Health News:New Clues to Possible Genetic Basis for ADHD 3Health News:Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment 2Health News:Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment 3Health News:Chest news briefs: CPAP may cause facial changes 2Health News:Medical home care approach improves efficiency and care at clinic for low-income families 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 3
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... Designed around the patented Interzeag ... 301 sets the trend in ... Ideal for routine screening and ... performance, accuracy and quality of ...
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
Medicine Products: